Clinical and pathological features of colorectal cancer patients in 2 groups
| Characteristics | Surgery (n = 16) | Surgery + HIPEC (n = 6) | Total (n = 22) |
|---|---|---|---|
| Age | |||
| Mean ± SD | 58.1 ± 13.5 | 54.2 ± 3.5 | 57.0 ± 11.7 |
| Range | 37–82 | 50–60 | 37–82 |
| Gender | |||
| Male | 10 | 3 | 13 |
| Female | 6 | 3 | 9 |
| Primary tumor site | |||
| Ascending colon | 3 | 1 | 4 |
| Transverse colon | 1 | 0 | 1 |
| Descending colon | 1 | 0 | 1 |
| Sigmoid colon | 4 | 3 | 7 |
| Rectum | 7 | 2 | 9 |
| Drug used in HIPEC | |||
| Mitomycin | 0 | 3 | 3 |
| Raltitrexed | 0 | 1 | 1 |
| Raltitrexed + mitomycin + oxaliplatin | 0 | 2 | 2 |
| Surgical modality | |||
| Radical surgery | 14 | 3 | 17 |
| Palliative surgery | 2 | 3 | 5 |
| TNM stage | |||
| Stage I | 2 | 1 | 3 |
| Stage II | 4 | 2 | 6 |
| Stage III | 8 | 0 | 8 |
| Stage IV | 2 | 3 | 5 |
| Metastatic sites | |||
| Liver | 2 | 2 | 4 |
| Adrenal gland | 1 | 0 | 1 |
| Abdominal cavity | 0 | 1 | 1 |
| CEA (normal: < 5.0 ng/mL) | |||
| Normal | 9 | 3 | 12 |
| Abnormal | 7 | 3 | 10 |
| CA19-9 (normal: < 30 U/mL) | |||
| Normal | 13 | 4 | 17 |
| Abnormal | 3 | 2 | 5 |
| CA72-4 (normal: < 6.9 U/mL) | |||
| Normal | 11 | 4 | 15 |
| Abnormal | 5 | 2 | 7 |